32. Beyond Selection Criteria: The Prognostic Impact of Macrotrabecular-Massive Hepatocellular Carcinoma in Liver Transplant
34. Idiopathic Vanishing Bile Duct Syndrome in a Young Female: A Case Report
35. Preliminary study for the development of a deep learning model to recognize flapping tremors in patients with hepatic encephalopathy
36. To B or not to B – Reappraisal the Staging for Single Hepatocellular Carcinoma Larger than 5 cm
99. A Tetraspan(in) Stabilizes Programmed Death-Ligand 1 during Hepatocellular Carcinoma Development
101. Bile acid-mediated activation of hepatic stellate cells and myeloid cell leukemia-1 triggers hepatocarcinogenesis
102. BRAP regulates autophagy affecting the proliferation and metastasis of liver cancer cells
104. Decreased NCOA5 expression promotes HCC Cell EMT and Metastasis via Transcriptional Derepression of ZEB1
108. Integrative approaches about natural products to determine the antioxidant effects and its active compounds by systemical and biochemical analysis
110. Oncogenic Roles of LAMC2 in Intrahepatic Cholangiocarcinoma via Promoting EGFR Translation
114. Tetraspan(in)-specific inhibitors blocked hepatic carcinogenesis via regulation of immune cell cytotoxicity
118. Exosomal miRNA as a Useful Biomarker for Predicting the Response of Atezolizumab and Bevacizumab Therapy in Patients with Hepatocellular Carcinoma
119. Genomic landscape of clinically actionable FGFR alterations in biliary tract cancer and across solid tumors
122. Targeted next generation sequencing (NGS) of cell free (cf) DNA in biliary tract cancer (BTC)
125. An Early Increase in IL-10 and TNF-α Levels Following Atezolizumab Plus Bevacizumab Treatment Predicts Survival in Advanced HCC Patients
126. An Early On-Treatment HBeAg-Seroclearance Is Not Associated with A Low Risk of Hepatocellular Carcinoma and Decompensated Liver Cirrhosis: A Multicenter Study
127. Baseline FIB-4 may be a risk factor of recurrence after SBRT in patients with HBV-related small HCC
128. Clinical Biomarker to Predict Efficacy of Nivolumab plus Ipilimumab in Advanced Heptocellular Carcinoma after Failure of Prior Atezolizumab plus Bevacizumab therapy
129. Distinct spatial distribution of tumor-associated neutrophil promotes hepatocellular carcinoma progression by regulating neutrophil extracellular traps
132. Body Mass Index as a Prelude to Hepatocellular Carcinoma and Metabolic Dysfunction associated Steatohepatitis Risk Factors in Patients with no Identified Risk Factor for Developing Hepatocellular Carcinoma
134. Significant male preference of TERT genetic alterations and HBV integration in young age HBV related HCC: implications for sex disparity
136. Sorted-Cell Sequencing on HCC Specimens Reveals EPS8L3 As a Key Player in Stemness Properties of CD24/CD13/EpCAM-Triple Positive HCC Cells
137. Tertiary Lymphoid Structure is a Prognostic Marker and Predict Immunotherapy Response in cHCC-CCA
138. Differential HBV replicative markers and covalently closed circular DNA transcription in immune active chronic hepatitis B with and without HBeAg
140. Direct-acting antiviral therapy for hepatitis C virus in patients with hepatocellular carcinoma: A nationwide cohort study
142. HCC risk factor after Sustained Virologic Response of Chronic Hepatitis C related Cirrhosis Patients Treated with Direct-Acting Antiviral Treatment
144. Incidence and Risk of Controlled Attenuation Parameter-Based Non-alcoholic Hepatosteatosis Development in Korean Patients with Chronic Hepatitis B